Clear-cell renal cell carcinoma tumors with an enhancer demethylator phenotype (TED) harbor a worse prognosis and derive less clinical benefit from immunotherapy. The TED phenotype may help predict immunotherapy resistance.

See related article by XXXX et al., p. 000

This content is only available via PDF.
You do not currently have access to this content.